The company reported an FDA clearance in 2025 followed by CaloPix’s IVDR certification, which it says enables Tribun Health to serve the global digital pathology market. The update signals regulatory traction for its digital pathology offering, supporting broader commercial deployment internationally.
The company reported an FDA clearance in 2025 followed by CaloPix’s IVDR certification, which it says enables Tribun Health to serve the global digital pathology market. The update signals regulatory traction for its digital pathology offering, supporting broader commercial deployment internationally.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
